CN119285527A - 色胺前药 - Google Patents

色胺前药 Download PDF

Info

Publication number
CN119285527A
CN119285527A CN202410898937.9A CN202410898937A CN119285527A CN 119285527 A CN119285527 A CN 119285527A CN 202410898937 A CN202410898937 A CN 202410898937A CN 119285527 A CN119285527 A CN 119285527A
Authority
CN
China
Prior art keywords
linear
alkyl
compound
branched
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202410898937.9A
Other languages
English (en)
Chinese (zh)
Inventor
N·布莱森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ruian Neuroscience Co
Original Assignee
Ruian Neuroscience Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ruian Neuroscience Co filed Critical Ruian Neuroscience Co
Publication of CN119285527A publication Critical patent/CN119285527A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202410898937.9A 2020-06-30 2021-06-30 色胺前药 Pending CN119285527A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202063045901P 2020-06-30 2020-06-30
US63/045,901 2020-06-30
US202063109095P 2020-11-03 2020-11-03
US63/109,095 2020-11-03
CN202180046999.1A CN115867533B (zh) 2020-06-30 2021-06-30 色胺前药
PCT/CA2021/050907 WO2022000091A1 (en) 2020-06-30 2021-06-30 Tryptamine prodrugs

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN202180046999.1A Division CN115867533B (zh) 2020-06-30 2021-06-30 色胺前药

Publications (1)

Publication Number Publication Date
CN119285527A true CN119285527A (zh) 2025-01-10

Family

ID=79032374

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202410898937.9A Pending CN119285527A (zh) 2020-06-30 2021-06-30 色胺前药
CN202410898893.XA Pending CN119285526A (zh) 2020-06-30 2021-06-30 色胺前药
CN202180046999.1A Active CN115867533B (zh) 2020-06-30 2021-06-30 色胺前药

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202410898893.XA Pending CN119285526A (zh) 2020-06-30 2021-06-30 色胺前药
CN202180046999.1A Active CN115867533B (zh) 2020-06-30 2021-06-30 色胺前药

Country Status (10)

Country Link
US (4) US11292765B2 (https=)
EP (1) EP4172145A4 (https=)
JP (2) JP7702654B2 (https=)
KR (2) KR102829078B1 (https=)
CN (3) CN119285527A (https=)
AU (1) AU2021302692A1 (https=)
CA (1) CA3181092A1 (https=)
IL (2) IL299506B2 (https=)
MX (1) MX2022016212A (https=)
WO (1) WO2022000091A1 (https=)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3152752A1 (en) 2019-10-01 2021-04-08 Thomas Henley Genetic engineering of fungi to modulate tryptamine expression
KR20220137081A (ko) 2020-02-04 2022-10-11 마인드셋 파마 인크. Cns 장애의 치료를 위한 세로토닌성 사이키델릭 작용제로서의 실로신 유도체
BR112022015379A2 (pt) 2020-02-04 2022-09-27 Mindset Pharma Inc Derivados de 3-pirrolidino-indol como agentes psicodélicos serotonérgicos para o tratamento de distúrbios do snc
WO2021226416A1 (en) 2020-05-08 2021-11-11 Psilera Inc. Novel compositions of matter and pharmaceutical compositions
CN119285527A (zh) * 2020-06-30 2025-01-10 瑞安神经科学公司 色胺前药
WO2022040802A1 (en) * 2020-08-26 2022-03-03 Magicmed Industries Inc. Glycosylated psilocybin derivatives and methods of using
EP4255422A4 (en) * 2020-12-03 2024-12-18 Mydecine Innovations Group Inc. NEW PSILOCIN ANALOGUE COMPOSITIONS AND METHODS OF THEIR SYNTHESIS
JP2024500397A (ja) * 2020-12-18 2024-01-09 コンパス パスファインダー リミテッド 治療用途のための修飾インドールアルカロイド
EP4155306A1 (en) 2021-01-15 2023-03-29 Beckley Psytech Limited Neuroactive ergoline analogue
US12534441B2 (en) 2021-01-15 2026-01-27 Beckley Psytech Limited Tryptamine analogues
US11312684B1 (en) 2021-02-10 2022-04-26 Eleusis Therapeutics Us, Inc. Pharmaceutically acceptable salts of psilocin and uses thereof
MX2023014630A (es) 2021-06-08 2024-01-30 Atai Therapeutics Inc Activadores de dimetoxifenilalquilamina de receptores de serotonina.
AU2022309017A1 (en) 2021-07-07 2024-01-25 Terran Biosciences Inc. N,n-dimethyltryptamine and related psychedlics and uses thereof
KR20240058859A (ko) 2021-08-12 2024-05-03 쿨레온 엘엘씨 환각성 및 비환각성 세로토닌 수용체 작용제 및 이의 제조 및 사용 방법
JP2024534801A (ja) * 2021-08-20 2024-09-26 テラン バイオサイエンシズ インコーポレイテッド サイロシンのプロドラッグ及び誘導体ならびにその使用
US20250011351A1 (en) 2021-11-12 2025-01-09 Terran Biosciences Inc. Psilocybin and o-acetylpsilocin, salts and solid state forms thereof
EP4444698A4 (en) * 2021-12-10 2025-07-09 Caamtech Inc PSILOCYBIN DERIVATIVES
US20250051278A1 (en) * 2021-12-14 2025-02-13 Reunion Neuroscience, Inc. Tryptamine prodrugs
EP4457203A4 (en) 2021-12-27 2025-12-17 Atai Therapeutics Inc AMINOTETRALINE ACTIVATORS OF SEROTONIN RECEPTORS
WO2023129956A2 (en) 2021-12-30 2023-07-06 ATAI Life Sciences AG Dimethyltryptamine analogues as nitric oxide delivery drugs
CN118984868A (zh) 2021-12-31 2024-11-19 恩派瑞安神经科学公司 用于产生精神药物生物碱的遗传修饰的生物体
WO2023133477A1 (en) * 2022-01-06 2023-07-13 Terran Biosciences, Inc. Salts and solid forms of 4-hydroxy-n,n-diisopropyltryptamine hemi-glutarate and hemi-succinate
WO2023147423A1 (en) * 2022-01-28 2023-08-03 Miralogx Llc Anxiolytic compounds, pharmaceutical compositions, and methods of treating anxiety and other disorders
WO2023168023A1 (en) 2022-03-04 2023-09-07 Reset Pharmaceuticals, Inc. Co-crystals or salts comprising psilocin
US20250186369A1 (en) * 2022-03-07 2025-06-12 Drexel University Compounds, compositions, and methods for treating, ameliorating, and/or prventing cocaine use disorder
AU2023234202A1 (en) * 2022-03-18 2024-11-07 Enveric Biosciences Canada Inc. Salts of c4-carboxylic acid- and c4-carbonothioate-substituted tryptamine derivatives and methods of using
CA3246245A1 (en) * 2022-03-18 2023-09-21 Enveric Biosciences Canada Inc. C4 CARBOXYLIC ACID SUBSTITUTED TRYPTAMINE DERIVATIVES AND METHODS OF USE
WO2023173196A1 (en) 2022-03-18 2023-09-21 Enveric Biosciences Canada Inc. C4-carboxylic acid-substituted tryptamine derivatives and methods of using
EP4493542A4 (en) * 2022-03-18 2026-03-04 Enveric Biosciences Canada Inc C4-CARBONOTHIOATE SUBSTITUTED TRYPTAMINE DERIVATIVES AND METHODS OF USE
CA3248442A1 (en) * 2022-04-13 2023-10-19 Caamtech, Inc. TRYPTAMINE DERIVATIVES
CN115521240B (zh) * 2022-06-01 2024-05-28 杭州奥泰生物技术股份有限公司 一种二甲基色胺半抗原和人工抗原及其制备方法与应用
CA3258595A1 (en) * 2022-07-27 2024-02-01 Reconnect Labs Ag HIGHLY SOLUBBLE FORMULATIONS BASED ON HARMIN
US12264131B2 (en) 2022-08-19 2025-04-01 Beckley Psytech Limited Pharmaceutically acceptable salts and compositions thereof
CN116283885B (zh) * 2022-12-01 2025-02-14 杭州奥泰生物技术股份有限公司 一种帕罗西汀半抗原和人工抗原及其制备方法与应用
WO2024145719A1 (en) * 2023-01-05 2024-07-11 Reunion Neuroscience Inc. Improved pharmacokinetics of tryptamine prodrugs
WO2024178051A2 (en) * 2023-02-22 2024-08-29 Caamtech, Inc. Tryptamine derivatives
US12343319B2 (en) 2023-05-01 2025-07-01 Atai Therapeutics, Inc. Compositions and methods for treatment of diseases and disorders
US12246005B2 (en) 2023-06-13 2025-03-11 Beckley Psytech Limited 5-methoxy-n,n-dimethyltryptamine (5-MeO-DMT) formulations
WO2025099725A1 (en) * 2023-11-09 2025-05-15 Hadasit Medical Research Services And Development Ltd. Conjugates and uses thereof
WO2025238416A1 (en) * 2024-05-16 2025-11-20 Mindset Pharma Inc. Indole derivatives, uses and compositions thereof
WO2025250900A1 (en) * 2024-05-30 2025-12-04 Caamtech, Inc. 4-hydroxy-n,n-diisopropyltryptaminium hydroglutarate
WO2026024591A1 (en) * 2024-07-22 2026-01-29 Reunion Neuroscience, Inc. Tryptamine prodrug solid forms

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3075992A (en) * 1958-09-12 1963-01-29 Sandoz Ltd Esters of indoles
BE582353A (https=) 1958-09-12
CH373381A (de) 1959-07-13 1963-11-30 Sandoz Ag Verfahren zur Herstellung neuer basischer Indol-Derivate
CH386422A (de) 1960-03-30 1965-01-15 Sandoz Ag Verfahren zur Herstellung neuer Ester der Indol-Reihe
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
DE69411143T2 (de) 1993-09-01 1998-10-22 Allelix Biopharma Tryptamin analoge mit 5-ht1d selektivität
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
US7655691B2 (en) * 2004-09-27 2010-02-02 Sard Howard P Indole compounds useful as serotonin selective agents
HUE032158T2 (en) 2008-10-31 2017-09-28 Univ Mississippi Process for the preparation of delta9-THC amino acid esters
US20180021326A1 (en) * 2016-07-23 2018-01-25 Paul Edward Stamets Compositions and methods for enhancing neuroregeneration and cognition by combining mushroom extracts containing active ingredients psilocin or psilocybin with erinacines or hericenones enhanced with niacin
CA3132731A1 (en) 2019-03-07 2020-09-10 University Of Padova Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic/psychotomimetic dosages and formulations
KR20220137081A (ko) 2020-02-04 2022-10-11 마인드셋 파마 인크. Cns 장애의 치료를 위한 세로토닌성 사이키델릭 작용제로서의 실로신 유도체
CN119285527A (zh) * 2020-06-30 2025-01-10 瑞安神经科学公司 色胺前药
JP2024500397A (ja) * 2020-12-18 2024-01-09 コンパス パスファインダー リミテッド 治療用途のための修飾インドールアルカロイド

Also Published As

Publication number Publication date
IL299506B2 (en) 2025-10-01
CN119285526A (zh) 2025-01-10
IL299506A (en) 2023-02-01
IL299506B1 (en) 2025-06-01
CA3181092A1 (en) 2022-01-06
US20250382267A1 (en) 2025-12-18
KR20250103811A (ko) 2025-07-07
US20250129023A1 (en) 2025-04-24
EP4172145A4 (en) 2024-08-21
AU2021302692A1 (en) 2023-01-19
WO2022000091A1 (en) 2022-01-06
US20210403425A1 (en) 2021-12-30
EP4172145A1 (en) 2023-05-03
JP7702654B2 (ja) 2025-07-04
JP2025143280A (ja) 2025-10-01
US20220177427A1 (en) 2022-06-09
CN115867533B (zh) 2024-07-23
US11292765B2 (en) 2022-04-05
KR20230028543A (ko) 2023-02-28
IL320601A (en) 2025-07-01
KR102829078B1 (ko) 2025-07-04
MX2022016212A (es) 2023-03-02
JP2023531311A (ja) 2023-07-21
CN115867533A (zh) 2023-03-28

Similar Documents

Publication Publication Date Title
CN115867533B (zh) 色胺前药
CN118679146A (zh) 色胺前药
US20040248983A1 (en) N-arylphenylacetamide derivatives and medicinal compositions containing the same
US10676438B2 (en) KCNQ2-5 channel activator
EA007008B1 (ru) Триамидзамещённые индолы, бензофураны и бензотиофены в качестве ингибиторов микросомального белка, переносящего триглицериды, (мтр) и/или ингибиторов секреции аполипопротеина в (аро в)
WO2005016326A2 (en) Analogs of thalidomide as potential angiogenesis inhibitors
TW201021798A (en) Amide acetate derivative having inhibitory activity on endothelial lipase
WO1999020620A1 (en) Isoquinoline derivative and drug
WO2016159577A2 (ko) 1,2 나프토퀴논 유도체 및 이의 제조방법
WO2018133670A1 (zh) 丁苯酞-替米沙坦杂合物及其制备方法和用途
WO2019007382A1 (zh) 吲哚甲酰胺类衍生物、其制备方法及其在医药上的应用
JPWO2005021486A1 (ja) エステル誘導体及びその医薬用途
CA3075324A1 (en) Deuterium atom-substituted indole formamide derivative, preparation method therefor, and medical applications thereof
HK40114252A (zh) 色胺前药
HK40114605A (zh) 色胺前药
HK40091294A (zh) 色胺前药
HK40091294B (zh) 色胺前药
HK40114112A (zh) 色胺前药
JP2021512958A (ja) 神経変性疾患を治療するための医薬及びその使用
JPWO2013018685A1 (ja) ラクタム誘導体及びその医薬用途
JPWO2011058943A1 (ja) Ｍｃｈｒ１アンタゴニスト活性を有する化合物とｎｐｙｙ５受容体アンタゴニスト活性を有する化合物を組み合わせてなる医薬組成物
CN110256461A (zh) 稠杂嘧啶衍生物及其制备方法和应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40114252

Country of ref document: HK